SERAAK2 as a Serotonin Receptor Ligand: Structural and Pharmacological In Vitro and In Vivo Evaluation
Molecules · 2025
DOI: 10.3390/molecules30234633 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Agnieszka A Kaczor und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Synthesis and Chemical Technology of Pharmaceutical Substances with Computer Modeling Laboratory, Faculty of Pharmacy, Medical Universi…. Hauptthemen laut MEDLINE: Receptor, Serotonin, 5-HT2A, Receptor, Serotonin, 5-HT1A, Receptors, Serotonin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Lublin, Medical University of Lublin, Poland, internal PB.
Abstract (Originalsprache)
Serotonin receptors, in particular 5-HT1A and 5-HT2A receptors, are important molecular targets for the central nervous system (CNS) disorders, such as schizophrenia, depression, anxiety disorders, memory deficits, and many others. Here, we present structural and pharmacological evaluation of a serotonin receptor ligand, SERAAK2, identified in a structure-based virtual screening campaign. Molecular docking studies revealed that SERAAK2 binds with its molecular targets via Asp3.32 as the main anchoring point, which is typical for orthosteric ligands of aminergic GPCRs. Molecular dynamics simulations confirmed the stability of the ligand binding poses in the studied receptors. MMGBSA calculations were in accordance with the receptor in vitro binding affinity studies, which indicated that SERAAK2 is a potent ligand of 5-HT1A and 5-HT2A receptors. It was also found that SERAAK2 displays favorable ADMET parameters. The demonstrated anxiolytic- and antidepressant-like effects of SERAAK2 in animal models, which may involve its interaction with 5-HT1A receptors, warrant further studies to confirm these activities and elucidate the underlying mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Synthesis and Chemical Technology of Pharmaceutical Substances with Computer Modeling Laboratory, Faculty of Pharmacy, Medical University of Lublin, 4A Chodźki St., PL-20093 Lublin, Poland.
- Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, PL-30688 Cracow, Poland.
- Department of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Str., 31-343 Krakow, Poland.
- School of Pharmacy, University of Eastern Finland, Yliopistonranta 1, P.O. Box 1627, FI-70211 Kuopio, Finland.
- Department of Pharmacology, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Universidade de Santiago de Compostela, Avda de Barcelona, E-15782 Santiago de Compostela, Spain.
- Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Travesía da Choupana s/n, E-15706 Santiago de Compostela, Spain.
ORCID-Profile: Agnieszka A Kaczor, Agata Zięba, Tadeusz Karcz, Katarzyna Szczepańska, Tuomo Laitinen, Marián Castro, Ewa Kędzierska
Förderung
- Medical University of Lublin
- Medical University of Lublin, Poland
- internal PB
- Biocenter Finland/DDCB
- CSC-IT Center for Science Ltd.
Zitieren
APA
Kaczor, A. A., Zięba, A., Karcz, T., Jastrzębski, M. K., Szczepańska, K., Laitinen, T., Castro, M., & Kędzierska, E. (2025). SERAAK2 as a Serotonin Receptor Ligand: Structural and Pharmacological In Vitro and In Vivo Evaluation. Molecules. https://doi.org/10.3390/molecules30234633
Vancouver
Kaczor AA, Zięba A, Karcz T, Jastrzębski MK, Szczepańska K, Laitinen T, et al. SERAAK2 as a Serotonin Receptor Ligand: Structural and Pharmacological In Vitro and In Vivo Evaluation. Molecules. 2025. doi:10.3390/molecules30234633
BibTeX
@article{Kaczor2025,
author = {Kaczor, Agnieszka A and Zięba, Agata and Karcz, Tadeusz and Jastrzębski, Michał K and Szczepańska, Katarzyna and Laitinen, Tuomo and Castro, Marián and Kędzierska, Ewa},
title = {SERAAK2 as a Serotonin Receptor Ligand: Structural and Pharmacological In Vitro and In Vivo Evaluation},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30234633}
}
EUVIMED